Your browser doesn't support javascript.
loading
Bat ASC2 suppresses inflammasomes and ameliorates inflammatory diseases.
Ahn, Matae; Chen, Vivian Chih-Wei; Rozario, Pritisha; Ng, Wei Lun; Kong, Pui San; Sia, Wan Rong; Kang, Adrian Eng Zheng; Su, Qi; Nguyen, Lan Huong; Zhu, Feng; Chan, Wharton O Y; Tan, Chee Wah; Cheong, Wan Shoo; Hey, Ying Ying; Foo, Randy; Guo, Fusheng; Lim, Yan Ting; Li, Xin; Chia, Wan Ni; Sobota, Radoslaw M; Fu, Nai Yang; Irving, Aaron T; Wang, Lin-Fa.
Affiliation
  • Ahn M; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore; SingHealth Duke-NUS Medicine Academic Clinical Program, Singapore 168753, Singapore; SingHealth PGY1 Residency Program, Singapore 169608, Singapore; Department of Internal Medicine, Singapore General Hos
  • Chen VC; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Rozario P; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Ng WL; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Kong PS; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Sia WR; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Kang AEZ; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Su Q; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Nguyen LH; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Zhu F; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Chan WOY; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Tan CW; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Cheong WS; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Hey YY; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Foo R; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Guo F; Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Lim YT; Functional Proteomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A(∗)STAR), Singapore 138673, Singapore; SingMass - National Mass Spectrometry Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research
  • Li X; Functional Proteomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A(∗)STAR), Singapore 138673, Singapore; SingMass - National Mass Spectrometry Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research
  • Chia WN; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Sobota RM; Functional Proteomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A(∗)STAR), Singapore 138673, Singapore; SingMass - National Mass Spectrometry Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research
  • Fu NY; Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Irving AT; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore; Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Haining 314400, China; Second Affiliated Hospital, Zhejiang University School of Medici
  • Wang LF; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore; SingHealth Duke-NUS Global Health Institute, Singapore 169857, Singapore. Electronic address: linfa.wang@duke-nus.edu.sg.
Cell ; 186(10): 2144-2159.e22, 2023 05 11.
Article in En | MEDLINE | ID: mdl-37172565
Bats are special in their ability to live long and host many emerging viruses. Our previous studies showed that bats have altered inflammasomes, which are central players in aging and infection. However, the role of inflammasome signaling in combating inflammatory diseases remains poorly understood. Here, we report bat ASC2 as a potent negative regulator of inflammasomes. Bat ASC2 is highly expressed at both the mRNA and protein levels and is highly potent in inhibiting human and mouse inflammasomes. Transgenic expression of bat ASC2 in mice reduced the severity of peritonitis induced by gout crystals and ASC particles. Bat ASC2 also dampened inflammation induced by multiple viruses and reduced mortality of influenza A virus infection. Importantly, it also suppressed SARS-CoV-2-immune-complex-induced inflammasome activation. Four key residues were identified for the gain of function of bat ASC2. Our results demonstrate that bat ASC2 is an important negative regulator of inflammasomes with therapeutic potential in inflammatory diseases.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ribonucleoproteins / Virus Diseases / Chiroptera / Apoptosis Regulatory Proteins / Inflammasomes Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cell Year: 2023 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ribonucleoproteins / Virus Diseases / Chiroptera / Apoptosis Regulatory Proteins / Inflammasomes Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cell Year: 2023 Type: Article